BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Week In Review | Jan 18, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BC Extra | Jan 17, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Week In Review | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
BC Extra | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
BC Week In Review | Oct 5, 2018
Clinical News

Arena's olorinab improves abdominal pain in Crohn's patients in Phase IIa

Arena Pharmaceuticals Inc. (NASDSAQ:ARNA) said olorinab (APD371) significantly improved average abdominal pain score from baseline to weeks four and eight in a Phase IIa trial to treat abdominal pain in patients with Crohn’s disease. The...
BC Week In Review | Aug 17, 2018
Clinical News

Eisai's Belviq does not increase MACE in CVOT for weight management drug

Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the...
BC Week In Review | Aug 3, 2018
Company News

Eisai grants CY Biotech Greater China rights to lorcaserin

Eisai Co. Ltd. (Tokyo:4523) granted exclusive rights to CY Biotech Co. Ltd. (Taipei, Taiwan) to develop and market obesity drug lorcaserin (APD356) in Greater China, including Hong Kong and Macao. Under the deal, Eisai will...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
Items per page:
1 - 10 of 622
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BC Week In Review | Jan 18, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BC Extra | Jan 17, 2019
Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Week In Review | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
BC Extra | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
BC Week In Review | Oct 5, 2018
Clinical News

Arena's olorinab improves abdominal pain in Crohn's patients in Phase IIa

Arena Pharmaceuticals Inc. (NASDSAQ:ARNA) said olorinab (APD371) significantly improved average abdominal pain score from baseline to weeks four and eight in a Phase IIa trial to treat abdominal pain in patients with Crohn’s disease. The...
BC Week In Review | Aug 17, 2018
Clinical News

Eisai's Belviq does not increase MACE in CVOT for weight management drug

Eisai Co. Ltd. (Tokyo:4523) said Belviq lorcaserin met the primary safety endpoint by not increasing the incidence of major adverse cardiovascular events (MACE), comprising CV death, non-fatal myocardial infarction (MI) and non-fatal stroke, in the...
BC Week In Review | Aug 3, 2018
Company News

Eisai grants CY Biotech Greater China rights to lorcaserin

Eisai Co. Ltd. (Tokyo:4523) granted exclusive rights to CY Biotech Co. Ltd. (Taipei, Taiwan) to develop and market obesity drug lorcaserin (APD356) in Greater China, including Hong Kong and Macao. Under the deal, Eisai will...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
Items per page:
1 - 10 of 622